REGENXBIO is a biotech company that develops gene therapy product candidates to address genetic defects or enable cells to produce therapeutic proteins. Its lead product candidate, RGX-314, is in Phase III clinical trial for wet age-related macular degeneration. The company also has other product candidates in various stages of clinical trials and preclinical development. REGENXBIO licenses its proprietary adeno-associated virus gene delivery platform to other companies and has a collaboration agreement with Neurimmune AG. The company was founded in 2008 and is based in Rockville, Maryland.